Business
TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management
TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA"), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced the appointment of Bertrand Le Bourdonnec, PhD as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management.
About this update from Tuhura Biosciences, Inc.
[{"type":"text","content":"Proven 20-year career in drug discovery and development track record leading to 12 pre-clinical/clinical candidates and 7 investigational new drug / clinical trial applications","length":176,"tagName":"p"},{"type":"text","content":"Extensive knowledge in the biochemistry and pharmacology of the Delta Opioid Receptor (DOR), the primary target in TuHURA's Antibody Drug Conjugate (ADC) and Antibody Peptide Conjugate (APC) technology platform","length":274,"tagName":"p"},{"type":"text","content":"Inventor of first-in-class spirocyclic DOR agonists as potential analgesics; clinical- stage products licensed to Pfizer","length":165,"tagName":"p"},{"type":"text","content":"Led the benevopran opioid-induced bowel dysfunction program to positive Phase IIb results: key value inflection point resulting in the acquisition of Adolor Corporation by Cubist Pharmaceuticals","length":234,"tagName":"p"},{"type":"text","content":"TAMPA, Fla., April 7, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA"), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced the appointment of Bertrand Le Bourdonnec, PhD as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management.","length":399,"tagName":"p"},{"type":"image","alt":"Bertrand Le Bourdonnec, PhD (PRNewsfoto/TuHURA Biosciences, Inc.)","displaySize":"","headline":null,"caption":"Bertrand Le Bourdonnec, PhD (PRNewsfoto/TuHURA Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/012cb665fe36250b699a345ac9b9d265"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LKBEvvkukjssxckzUIZ.vQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/012cb665fe36250b699a345ac9b9d265","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/2657908/Tuhura_Biosciences_Inc_Bert_Le_Bourdonnec_ID_060b81c9d124.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Dr. Le Bourdonnec is a seasoned biotech executive with broad scientific and leadersh...